Dr. Reddy seeks nod for DCGI approval for Phase 3 clinical trials of Sputnik V in India

Dr Reddy’s Laboratories has applied permission to the Drugs Controller General of India (DCGI) for conducting the phase-3 human clinical trials of Sputnik V, Russian coronavirus vaccine against COVID-19 in India, according to the sources.

“Dr Reddy’s Laboratories has applied to the DCGI seeking permission to conduct phase-3 human clinical trials of the Sputnik V vaccine against COVID-19 developed by Russia. The DCGI will carry out a technical evaluation of the application before giving its approval,” according to the sources.

Dr. Reddy has partnered with Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V as well as its distribution.
Upon regulatory approval in India, RDIF will supply to Dr Reddy’s 100 million doses of the vaccine, the firm said last month.

LEAVE A REPLY

Please enter your comment!
Please enter your name here